N-terminal targeting of androgen receptor variant enhances response of castration resistant prostate cancer to taxane chemotherapy.
Ontology highlight
ABSTRACT: Taxane-based chemotherapy is an effective treatment for castration-resistant-prostate cancer (CRPC) via stabilization of microtubules. Previous studies identified that the inhibitory effect of microtubule-targeting chemotherapy on androgen receptor (AR) activity was conferred by interfering with AR intracellular trafficking. The N-terminal domain (NTD) of AR was identified as a tubulin-interacting domain that can be effectively targeted by the novel small molecule inhibitor, EPI. Taken together this evidence provided the rationale that targeting AR nuclear translocation and activity via a combination of an antagonist of the AR NTD and taxane-based chemotherapy may enhance the therapeutic response in CRPC. The present study investigated the anti-tumor efficacy of a combination of EPI with D
SUBMITTER: Martin SK
PROVIDER: S-EPMC4433435 | biostudies-literature | 2014 Nov
REPOSITORIES: biostudies-literature
ACCESS DATA